Dinaciclib in Treating Patients With Stage IV Melanoma

Phase 2 Active not recruiting 72 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2009-07-01
Primary completion: 2013-10-22
Completion: 2027-03-19

Outcome

Met primary endpoint

paper Although the null hypothesis of 1-year OS was rejected PMID 39342463 ↗

Publications

Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 2025 Jan 1;131(1):e35587. doi: 10.1002/cncr.35587. Epub 2024 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dinaciclib	Small molecule	50 mg/m2	Intravenous